Terms: = Lymphoma AND REL, I-Rel, 5966, ENSG00000162924, C-Rel AND Treatment
73 results:
1. Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
Trabolsi A; Arumov A; Schatz JH
Blood Cancer J; 2024 Feb; 14(1):27. PubMed ID: 38331870
[TBL] [Abstract] [Full Text] [Related]
2. Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis.
Derigs P; Bethge WA; Krämer I; Holtick U; von Tresckow B; Ayuk F; Penack O; Vucinic V; von Bonin M; Baldus C; Mougiakakos D; Wulf G; Schnetzke U; Stelljes M; Fante M; Schroers R; Kroeger N; Dreger P;
Transplant Cell Ther; 2023 Dec; 29(12):750-756. PubMed ID: 37709204
[TBL] [Abstract] [Full Text] [Related]
3. Conferone, a coumarin from
Rafatpanah H; Golizadeh M; Mahdifar M; Mahdavi S; Iranshahi M; Rassouli FB
Int J Immunopathol Pharmacol; 2023; 37():3946320231197592. PubMed ID: 37688389
[TBL] [Abstract] [Full Text] [Related]
4. Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.
Russler-Germain DA; Krysiak K; Ramirez C; Mosior M; Watkins MP; Gomez F; Skidmore ZL; Trani L; Gao F; Geyer S; Cashen AF; Mehta-Shah N; Kahl BS; Bartlett NL; Alderuccio JP; Lossos IS; Ondrejka SL; Hsi ED; Martin P; Leonard JP; Griffith M; Griffith OL; Fehniger TA
Blood Adv; 2023 Sep; 7(18):5524-5539. PubMed ID: 37493986
[TBL] [Abstract] [Full Text] [Related]
5. Quality-adjusted survival time without symptoms or toxicity of acalabrutinib with or without obinutuzumab in patients with treatment-naive chronic lymphocytic leukemia.
Sharman JP; Miranda P; Roos J; Emeribe U; Cai L; Liljas B; Gaitonde P
Leuk Lymphoma; 2023; 64(7):1243-1252. PubMed ID: 37221877
[TBL] [Abstract] [Full Text] [Related]
6. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with relapsed/Refractory Large B Cell lymphoma.
Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA
Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322
[TBL] [Abstract] [Full Text] [Related]
7. Transformation of FL into DLBCL with a PMBL gene expression signature.
Loveday T; Duns G; Rimsza LM; Rech KL; Cook JR; Robetorye RS; Rosenthal AC; Ramsower CA; Yip TK; McKinney CL; Swerdlow SH; Bhavsar S; Steidl C; Gibson SE
Blood Adv; 2023 Mar; 7(6):893-899. PubMed ID: 36240289
[TBL] [Abstract] [Full Text] [Related]
8. Phase 1/dose expansion trial of brentuximab vedotin and lenalidomide in relapsed or refractory diffuse large B-cell lymphoma.
Ward JP; Berrien-Elliott MM; Gomez F; Luo J; Becker-Hapak M; Cashen AF; Wagner-Johnston ND; Maddocks K; Mosior M; Foster M; Krysiak K; Schmidt A; Skidmore ZL; Desai S; Watkins MP; Fischer A; Griffith M; Griffith OL; Fehniger TA; Bartlett NL
Blood; 2022 Mar; 139(13):1999-2010. PubMed ID: 34780623
[TBL] [Abstract] [Full Text] [Related]
9. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for relapsed or Refractory Classical Hodgkin lymphoma.
Moskowitz AJ; Shah G; Schöder H; Ganesan N; Drill E; Hancock H; Davey T; Perez L; Ryu S; Sohail S; Santarosa A; Galasso N; Neuman R; Liotta B; Blouin W; Kumar A; Lahoud O; Batlevi CL; Hamlin P; Straus DJ; Rodriguez-Rivera I; Owens C; Caron P; Intlekofer AM; Hamilton A; Horwitz SM; Falchi L; Joffe E; Johnson W; Lee C; Palomba ML; Noy A; Matasar MJ; Pongas G; Salles G; Vardhana S; Sanin BW; von Keudell G; Yahalom J; Dogan A; Zelenetz AD; Moskowitz CH
J Clin Oncol; 2021 Oct; 39(28):3109-3117. PubMed ID: 34170745
[TBL] [Abstract] [Full Text] [Related]
10. Hematopoietic stem cell transplantation does not increase the risk of infection-related complications for pediatric patients with Hodgkin and non-Hodgkin lymphomas: A multicenter nationwide study.
Zając-Spychała O; Wachowiak J; Czyżewski K; Dziedzic M; Wysocki M; Zalas-Więcek P; Szmydki-Baran A; Hutnik Ł; Matysiak M; Małas Z; Badowska W; Gryniewicz-Kwiatkowska O; Gietka A; Dembowska-Bagińska B; Semczuk K; Dzierżanowska-Fangrat K; Bartnik M; Ociepa T; Urasiński T; Frączkiewicz J; Salamonowicz M; Kałwak K; Gorczyńska E; Chybicka A; Irga-Jaworska N; Bień E; Drożyńska E; Chełmecka-Wiktorczyk L; Balwierz W; Zak I; Pierlejewski F; Młynarski W; Urbanek-Dądela A; Karolczyk G; Stolpa W; Sobol-Milejska G; Płonowski M; Krawczuk-Rybak M; Musiał J; Chaber R; Gamrot-Pyka Z; Woszczyk M; Tomaszewska R; Szczepański T; Kowalczyk J; Styczyński J
Transpl Infect Dis; 2020 Aug; 22(4):e13292. PubMed ID: 32285579
[TBL] [Abstract] [Full Text] [Related]
11. Allogeneic Stem Cell Transplantation Provides Durable Remission in Patients with Primary Mediastinal Large B Cell lymphoma.
Herrera AF; Chen L; Khajavian S; Chase M; Darrah J; Maloney D; Ho VT; Soiffer RJ; Antin JH; Forman SJ; Nademanee AP; Chen YB; Armand P; Shadman M
Biol Blood Marrow Transplant; 2019 Dec; 25(12):2383-2387. PubMed ID: 31394277
[TBL] [Abstract] [Full Text] [Related]
12. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (rel) network.
Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
[TBL] [Abstract] [Full Text] [Related]
13. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer.
Konczalla L; Perez DR; Wenzel N; Wolters-Eisfeld G; Klemp C; Lüddeke J; Wolski A; Landschulze D; Meier C; Buchholz A; Yao D; Hofmann BT; Graß JK; Spriestersbach SL; Grupp K; Schumacher U; Betzel C; Kapis S; Nuguid T; Steinberg P; Püschel K; Sauter G; Bockhorn M; Uzunoglu FG; Izbicki JR; Güngör C; El Gammal AT
Int J Cancer; 2020 Mar; 146(6):1618-1630. PubMed ID: 31291468
[TBL] [Abstract] [Full Text] [Related]
14. lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (rel) clinical network.
Rattotti S; Ferretti VV; Rusconi C; Rossi A; Fogazzi S; Baldini L; Pioltelli P; Balzarotti M; Farina L; Ferreri AJM; Laszlo D; Speziale V; Varettoni M; Sciarra R; Morello L; Tedeschi A; Frigeni M; Defrancesco I; Zerbi C; Flospergher E; Nizzoli ME; Morra E; Arcaini L;
Hematol Oncol; 2019 Apr; 37(2):160-167. PubMed ID: 30726562
[TBL] [Abstract] [Full Text] [Related]
15. Where does PD-1 blockade fit in HL therapy?
Herrera AF
Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):213-220. PubMed ID: 30504313
[TBL] [Abstract] [Full Text] [Related]
16. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract] [Full Text] [Related]
17. Expression of ribosomal and actin network proteins and immunochemotherapy resistance in diffuse large B cell lymphoma patients.
Bram Ednersson S; Stenson M; Stern M; Enblad G; Fagman H; Nilsson-Ehle H; Hasselblom S; Andersson PO
Br J Haematol; 2018 Jun; 181(6):770-781. PubMed ID: 29767447
[TBL] [Abstract] [Full Text] [Related]
18. A phase 1 study of ibrutinib in combination with R-ICE in patients with relapsed or primary refractory DLBCL.
Sauter CS; Matasar MJ; Schoder H; Devlin SM; Drullinsky P; Gerecitano J; Kumar A; Noy A; Palomba ML; Portlock CS; Straus DJ; Zelenetz AD; McCall SJ; Miller ST; Courtien AI; Younes A; Moskowitz CH
Blood; 2018 Apr; 131(16):1805-1808. PubMed ID: 29386196
[TBL] [Abstract] [Full Text] [Related]
19. Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor lymphoma.
Herrera AF; Rodig SJ; Song JY; Kim Y; Griffin GK; Yang D; Nikolaenko L; Mei M; Bedell V; Dal Cin P; Pak C; Alyea EP; Budde LE; Chen R; Chen YB; Chan WC; Cutler CS; Ho VT; Koreth J; Krishnan A; Murata-Collins JL; Nikiforow S; Palmer J; Pihan GA; Pillai R; Popplewell L; Rosen ST; Siddiqi T; Sohani AR; Zain J; Kwak LW; Weisenburger DD; Weinstock DM; Soiffer RJ; Antin JH; Forman SJ; Nademanee AP; Armand P
Biol Blood Marrow Transplant; 2018 Mar; 24(3):514-520. PubMed ID: 29196080
[TBL] [Abstract] [Full Text] [Related]
20. HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma.
Jia YJ; Liu ZB; Wang WG; Sun CB; Wei P; Yang YL; You MJ; Yu BH; Li XQ; Zhou XY
Leukemia; 2018 Mar; 32(3):703-711. PubMed ID: 29135973
[TBL] [Abstract] [Full Text] [Related]
[Next]
